The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs

Yung Hung Luo, Hsiang Ling Ho, Chun Ming Tsai, Jen Fu Shih, Chao Hua Chiu, Shinn Liang Lai, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng, Teh Ying Chou, Yuh Min Chen

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Objectives: An increased incidence of multiple primary malignancies has been found in recent decades. However, the nature of the association between the epidermal growth factor receptor (EGFR) mutation status and multiple primary malignancies in patients with adenocarcinoma of the lungs is not clearly understood at this time. Methods: We retrospectively reviewed the data of our patients with adenocarcinoma of the lungs, and evaluated the association between the tumor EGFR mutation status and multiple primary malignancies. Results: From December 2008 to November 2011, 655 pulmonary adenocarcinoma patients with tumor EGFR mutation data were available for analysis. Of them, 359 had EGFR mutations (including 336 classic EGFR mutations), 63 had double primary malignancies, and 7 had triple primary malignancies. Patients with classic EGFR mutations had a higher incidence of multiple primary malignancies than those without (P=0.042). Multiple primary malignancies occurred more frequently in patients with exon 19 mutations (including insertions, point mutations, or deletions) or exon 19 deletions than in patients without (P=0.037 and 0.032, respectively). Patients with any EGFR mutations or classic EGFR mutations survived longer than those who did not (P<0.001 and <0.001, respectively). Patients with multiple primary malignancies survived for a longer period than those without (P=0.006). Conclusions: Multiple primary malignancies occurred more frequently in patients with classic EGFR mutations, especially those with exon 19 deletions.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Epidermal Growth Factor Receptor
Mutation
Neoplasms
Exons
Adenocarcinoma of lung
Insertional Mutagenesis
Incidence
Point Mutation

Keywords

  • adenocarcinoma of the Lungs
  • exon 19 mutation
  • exon 21 mutation
  • multiple primary malignancies
  • tumor epidermal growth factor receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs. / Luo, Yung Hung; Ho, Hsiang Ling; Tsai, Chun Ming; Shih, Jen Fu; Chiu, Chao Hua; Lai, Shinn Liang; Lee, Yu Chin; Perng, Reury Perng; Whang-Peng, Jacqueline; Chou, Teh Ying; Chen, Yuh Min.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 38, No. 2, 01.01.2015, p. 147-151.

Research output: Contribution to journalReview article

Luo, Yung Hung ; Ho, Hsiang Ling ; Tsai, Chun Ming ; Shih, Jen Fu ; Chiu, Chao Hua ; Lai, Shinn Liang ; Lee, Yu Chin ; Perng, Reury Perng ; Whang-Peng, Jacqueline ; Chou, Teh Ying ; Chen, Yuh Min. / The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2015 ; Vol. 38, No. 2. pp. 147-151.
@article{361fb887208446b98c4eaf65ddde8e04,
title = "The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs",
abstract = "Objectives: An increased incidence of multiple primary malignancies has been found in recent decades. However, the nature of the association between the epidermal growth factor receptor (EGFR) mutation status and multiple primary malignancies in patients with adenocarcinoma of the lungs is not clearly understood at this time. Methods: We retrospectively reviewed the data of our patients with adenocarcinoma of the lungs, and evaluated the association between the tumor EGFR mutation status and multiple primary malignancies. Results: From December 2008 to November 2011, 655 pulmonary adenocarcinoma patients with tumor EGFR mutation data were available for analysis. Of them, 359 had EGFR mutations (including 336 classic EGFR mutations), 63 had double primary malignancies, and 7 had triple primary malignancies. Patients with classic EGFR mutations had a higher incidence of multiple primary malignancies than those without (P=0.042). Multiple primary malignancies occurred more frequently in patients with exon 19 mutations (including insertions, point mutations, or deletions) or exon 19 deletions than in patients without (P=0.037 and 0.032, respectively). Patients with any EGFR mutations or classic EGFR mutations survived longer than those who did not (P<0.001 and <0.001, respectively). Patients with multiple primary malignancies survived for a longer period than those without (P=0.006). Conclusions: Multiple primary malignancies occurred more frequently in patients with classic EGFR mutations, especially those with exon 19 deletions.",
keywords = "adenocarcinoma of the Lungs, exon 19 mutation, exon 21 mutation, multiple primary malignancies, tumor epidermal growth factor receptor",
author = "Luo, {Yung Hung} and Ho, {Hsiang Ling} and Tsai, {Chun Ming} and Shih, {Jen Fu} and Chiu, {Chao Hua} and Lai, {Shinn Liang} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng and Chou, {Teh Ying} and Chen, {Yuh Min}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/COC.0b013e318292f88c",
language = "English",
volume = "38",
pages = "147--151",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs

AU - Luo, Yung Hung

AU - Ho, Hsiang Ling

AU - Tsai, Chun Ming

AU - Shih, Jen Fu

AU - Chiu, Chao Hua

AU - Lai, Shinn Liang

AU - Lee, Yu Chin

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

AU - Chou, Teh Ying

AU - Chen, Yuh Min

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: An increased incidence of multiple primary malignancies has been found in recent decades. However, the nature of the association between the epidermal growth factor receptor (EGFR) mutation status and multiple primary malignancies in patients with adenocarcinoma of the lungs is not clearly understood at this time. Methods: We retrospectively reviewed the data of our patients with adenocarcinoma of the lungs, and evaluated the association between the tumor EGFR mutation status and multiple primary malignancies. Results: From December 2008 to November 2011, 655 pulmonary adenocarcinoma patients with tumor EGFR mutation data were available for analysis. Of them, 359 had EGFR mutations (including 336 classic EGFR mutations), 63 had double primary malignancies, and 7 had triple primary malignancies. Patients with classic EGFR mutations had a higher incidence of multiple primary malignancies than those without (P=0.042). Multiple primary malignancies occurred more frequently in patients with exon 19 mutations (including insertions, point mutations, or deletions) or exon 19 deletions than in patients without (P=0.037 and 0.032, respectively). Patients with any EGFR mutations or classic EGFR mutations survived longer than those who did not (P<0.001 and <0.001, respectively). Patients with multiple primary malignancies survived for a longer period than those without (P=0.006). Conclusions: Multiple primary malignancies occurred more frequently in patients with classic EGFR mutations, especially those with exon 19 deletions.

AB - Objectives: An increased incidence of multiple primary malignancies has been found in recent decades. However, the nature of the association between the epidermal growth factor receptor (EGFR) mutation status and multiple primary malignancies in patients with adenocarcinoma of the lungs is not clearly understood at this time. Methods: We retrospectively reviewed the data of our patients with adenocarcinoma of the lungs, and evaluated the association between the tumor EGFR mutation status and multiple primary malignancies. Results: From December 2008 to November 2011, 655 pulmonary adenocarcinoma patients with tumor EGFR mutation data were available for analysis. Of them, 359 had EGFR mutations (including 336 classic EGFR mutations), 63 had double primary malignancies, and 7 had triple primary malignancies. Patients with classic EGFR mutations had a higher incidence of multiple primary malignancies than those without (P=0.042). Multiple primary malignancies occurred more frequently in patients with exon 19 mutations (including insertions, point mutations, or deletions) or exon 19 deletions than in patients without (P=0.037 and 0.032, respectively). Patients with any EGFR mutations or classic EGFR mutations survived longer than those who did not (P<0.001 and <0.001, respectively). Patients with multiple primary malignancies survived for a longer period than those without (P=0.006). Conclusions: Multiple primary malignancies occurred more frequently in patients with classic EGFR mutations, especially those with exon 19 deletions.

KW - adenocarcinoma of the Lungs

KW - exon 19 mutation

KW - exon 21 mutation

KW - multiple primary malignancies

KW - tumor epidermal growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=84926417837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926417837&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e318292f88c

DO - 10.1097/COC.0b013e318292f88c

M3 - Review article

C2 - 23608835

AN - SCOPUS:84926417837

VL - 38

SP - 147

EP - 151

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -